Nina Bhardwaj

List of Publications by Citations

268 papers	24,119 citations	74 h-index	153 g-index
292 ext. papers	28,009 ext. citations	11.1 avg, IF	6.88 L-index

#	Paper	IF	Citations
268	Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. *Nature*, **1998**, 392, 86-9	50.4	1975
267	Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. *Journal of Experimental Medicine*, **2000**, 191, 423-34	16.6	1209
266	Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. *Journal of Experimental Medicine*, **2001**, 193, 233-8	16.6	1162
265	Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. *Journal of Experimental Medicine*, **1998**, 188, 1359-68	16.6	1066
264	Immunology of COVID-19: Current State of the Science. *Immunity*, **2020**, 52, 910-941	32.3	962
263	Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. *Journal of Immunological Methods*, **1996**, 196, 121-35	2.5	590
262	Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. *Journal of Experimental Medicine*, **1998**, 188, 2163-73	16.6	546
261	Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. *Immunity*, **2016**, 44, 924-38	32.3	544
260	Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. *Journal of Clinical Investigation*, **2005**, 115, 3265-75	15.9	505
259	Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 1814-9	11.5	461
258	Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. *Cancer Cell*, **2016**, 30, 324-336	24.3	426
257	A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. *Nature Medicine*, **2018**, 24, 1178-1191	50.5	404
256	Tumor-specific killer cells in paraneoplastic cerebellar degeneration. *Nature Medicine*, **1998**, 4, 1321-4	50.5	393
255	Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. *Journal of Clinical Investigation*, **1999**, 104, 173-80	15.9	359
254	Dendritic cell-based immunotherapy. *Cell Research*, **2017**, 27, 74-95	24.7	328
253	Phenotypic properties of transmitted founder HIV-1. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 6626-33	11.5	293
252	Plasmacytoid dendritic cells: linking innate and adaptive immunity. *Journal of Virology*, **2005**, 79, 17-27	6.6	283

251	Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. *Journal of Virology*, **2004**, 78, 5223-32	6.6	281
250	miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. *Cancer Cell*, **2011**, 20, 104-18	24.3	278
249	Manipulating dendritic cell biology for the active immunotherapy of cancer. *Blood*, **2004**, 104, 2235-46	2.2	278
248	Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. *Blood*, **2003**, 101, 3520-6	2.2	277
247	Combining radiotherapy and immunotherapy: a revived partnership. *International Journal of Radiation Oncology Biology Physics*, **2005**, 63, 655-66	4	265
246	CD8 epitope escape and reversion in acute HCV infection. *Journal of Experimental Medicine*, **2004**, 200, 1593-604	16.6	263
245	Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 20429-34	11.5	257
244	Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 8947-52	11.5	255
243	Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. *Arthritis and Rheumatism*, **1992**, 35, 35-42		244
242	Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. *Cancer Immunology Research*, **2014**, 2, 410-22	12.5	236
241	Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors. *Journal of Experimental Medicine*, **1996**, 184, 2433-8	16.6	220
240	A Monocyte Conditioned Medium Is More Effective Than Defined Cytokines in Mediating the Terminal Maturation of Human Dendritic Cells. *Blood*, **1997**, 90, 3640-3646	2.2	207
239	Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. *Journal of Immunology*, **2008**, 181, 776-84	5.3	207
238	Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. *Journal of Immunology*, **2001**, 167, 4844-52	5.3	207
237	Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. *Journal of Experimental Medicine*, **2005**, 201, 891-902	16.6	198
236	HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. *Journal of Clinical Investigation*, **2008**, 118, 3431-9	15.9	181
235	A conserved dendritic-cell regulatory program limits antitumour immunity. *Nature*, **2020**, 580, 257-262	50.4	179
234	A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. *Aids*, **1999**, 13, 767-77	3.5	176

233	The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. *Blood*, **2005**, 106, 167-74	2.2	166
232	Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. *Journal of Clinical Investigation*, **2000**, 105, R9-R14	15.9	160
231	Dendritic cells resurrect antigens from dead cells. *Trends in Immunology*, **2001**, 22, 141-8	14.4	157
230	DCs and NK cells: critical effectors in the immune response to HIV-1. *Nature Reviews Immunology*, **2011**, 11, 176-86	36.5	152
229	A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. *Vaccine*, **2002**, 20 Suppl 4, A8-A22	4.1	152
228	Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. *Clinical Cancer Research*, **2012**, 18, 6748-57	12.9	146
227	Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. *Trends in Cancer*, **2018**, 4, 119-137	12.5	144
226	Evidence of dysregulation of dendritic cells in primary HIV infection. *Blood*, **2010**, 116, 3839-52	2.2	137
225	LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. *Journal of Clinical Investigation*, **2010**, 120, 4415-24	15.9	135
224	Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. *Journal of Virology*, **2002**, 76, 7528-34	6.6	131
223	A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. *Cell*, **2020**, 183, 347-362.e24	56.2	128
222	Therapeutic cancer vaccines. *Nature Reviews Cancer*, **2021**, 21, 360-378	31.3	125
221	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. *Nature Communications*, **2018**, 9, 3503	17.4	124
220	The Human Vaccines Project: A roadmap for cancer vaccine development. *Science Translational Medicine*, **2016**, 8, 334ps9	17.5	115
219	Toll-like receptor agonists: are they good adjuvants?. *Cancer Journal (Sudbury, Mass)*, **2010**, 16, 382-91	2.2	115
218	Tethering and tickling: a new role for the phosphatidylserine receptor. *Journal of Cell Biology*, **2001**, 155, 501-4	7.3	115
217	Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2013**, 63, 280-8	3.1	113
216	Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. *Journal of Immunology*, **2000**, 165, 1182-90	5.3	112

215	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. *Cell*, **2020**, 183, 818-834.e13	56.2	105
214	Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells. *Blood*, **2003**, 102, 4448-55	2.2	104
213	Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-producing and partially matured phenotype. *Journal of Clinical Investigation*, **2011**, 121, 1088-101	15.9	102
212	The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of human dendritic-cell immunostimulatory function. *Blood*, **2006**, 108, 947-55	2.2	99
211	The distinctive features of influenza virus infection of dendritic cells. *Immunobiology*, **1998**, 198, 552-67	3.4	97
210	Danger signals: a time and space continuum. *Trends in Molecular Medicine*, **2004**, 10, 251-7	11.5	95
209	Human immunodeficiency virus type 1 modified to package Simian immunodeficiency virus Vpx efficiently infects macrophages and dendritic cells. *Journal of Virology*, **2011**, 85, 6263-74	6.6	90
208	Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus. *Aids*, **2002**, 16, 1319-29	3.5	89
207	Harnessing the immune system to treat cancer. *Journal of Clinical Investigation*, **2007**, 117, 1130-6	15.9	88
206	Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. *European Journal of Immunology*, **2001**, 31, 3432-42	6.1	87
205	Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. *Cancer Immunology Research*, **2014**, 2, 720-4	12.5	86
204	Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. *Cancer Immunology, Immunotherapy*, **2013**, 62, 811-22	7.4	85
203	CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. *PLoS ONE*, **2010**, 5, e11144	3.7	84
202	Dendritic cells as targets for therapy in rheumatoid arthritis. *Nature Reviews Rheumatology*, **2009**, 5, 566-71	8.1	82
201	Directing dendritic cell immunotherapy towards successful cancer treatment. *Immunotherapy*, **2010** , 2, 37-56	3.8	80
200	Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. *Journal of Immunological Methods*, **2001**, 258, 111-26	2.5	80
199	Activation of Toll-like receptor-2 by tumor associated matrix metalloproteinase-2 modulates dendritic cell function **2014**, 2,		78
198	Melanoma progression is associated with NK cell exhaustion **2014**, 2, O6		78

197	ATIM-31. PHASE I STUDY OF TUMOR TREATMENT FIELDS AND A PERSONALIZED MUTATION-DERIVED TUMOR VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. *Neuro-Oncology*, **2018**, 20, vi8-vi8	1	78
196	Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. *Journal of Virology*, **1998**, 72, 9788-94	6.6	75
195	CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. *Cancer Immunology, Immunotherapy*, **2011**, 60, 1137-46	7.4	74
194	Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Valpha24 NKT cell compartment. *European Journal of Immunology*, **2003**, 33, 588-96	6.1	73
193	MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. *Clinical Cancer Research*, **2011**, 17, 4309-19	12.9	72
192	Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. *Journal of Virology*, **2001**, 75, 2142-53	6.6	70
191	Processing and presentation of antigens by dendritic cells: implications for vaccines. *Trends in Molecular Medicine*, **2001**, 7, 388-94	11.5	70
190	Large-Scale Human Dendritic Cell Differentiation Revealing Notch-Dependent Lineage Bifurcation and Heterogeneity. *Cell Reports*, **2018**, 24, 1902-1915.e6	10.6	68
189	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. *European Urology*, **2018**, 73, 751-759	10.2	67
188	Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. *Cancer Immunity*, **2007**, 7, 11		65
187	A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. *Vaccine*, **2009**, 27, 6088-94	4.1	64
186	Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. *Cancer Immunology Research*, **2015**, 3, 278-287	12.5	63
185	Dendritic cell dysregulation during HIV-1 infection. *Immunological Reviews*, **2013**, 254, 170-89	11.3	63
184	Dendritic cell subsets and locations. *International Review of Cell and Molecular Biology*, **2019**, 348, 1-68	6	62
183	Reversal of natural killer cell exhaustion by TIM-3 blockade. *OncoImmunology*, **2014**, 3, e946365	7.2	62
182	Cancer immunotherapy: dendritic-cell vaccines on the move. *Nature*, **2015**, 519, 300-1	50.4	61
181	Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial. *Clinical Cancer Research*, **2018**, 24, 4937-4948	12.9	61
180	Phosphorylated 4E-BP1 is associated with poor survival in melanoma. *Clinical Cancer Research*, **2009**, 15, 2872-8	12.9	61

179	Recent advances in dendritic cell biology. *Journal of Clinical Immunology*, **2005**, 25, 177-88	5.7	61
178	Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2016**, 71, 246-53	3.1	58
177	Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. *Journal of Virology*, **2004**, 78, 6151-61	6.6	57
176	Towards superior dendritic-cell vaccines for cancer therapy. *Nature Biomedical Engineering*, **2018**, 2, 341-346	19	55
175	Dendritic cells in progression and pathology of HIV infection. *Trends in Immunology*, **2014**, 35, 114-22	14.4	54
174	Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. *Immunology Letters*, **1999**, 66, 121-8	4.1	54
173	Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis. *Journal of Cutaneous Pathology*, **1998**, 25, 79-88	1.7	53
172	Activation of the noncanonical NF-Ƀ pathway by HIV controls a dendritic cell immunoregulatory phenotype. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 14122-7	11.5	52
171	In situ vaccination for the treatment of cancer. *Immunotherapy*, **2016**, 8, 315-30	3.8	51
170	Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. *Blood*, **2006**, 107, 1963-9	2.2	51
169	Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. *European Urology*, **2019**, 76, 599-603	10.2	50
168	Plasmacytoid dendritic cells in HIV infection. *Advances in Experimental Medicine and Biology*, **2013**, 762, 71-107	3.6	50
167	Oligonucleotide motifs that disappear during the evolution of influenza virus in humans increase alpha interferon secretion by plasmacytoid dendritic cells. *Journal of Virology*, **2011**, 85, 3893-904	6.6	50
166	Modulation of innate immunity in the tumor microenvironment. *Cancer Immunology, Immunotherapy*, **2016**, 65, 1261-8	7.4	49
165	Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. *Modern Pathology*, **2012**, 25, 1000-10	9.8	49
164	Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses. *Current Opinion in Immunology*, **2002**, 14, 471-7	7.8	48
163	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials **2016**, 4, 15		47
162	TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. *Cancer Research*, **2011**, 71, 5467-76	10.1	47

161	Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. *Cancer Research*, **2008**, 68, 9441-50	10.1	47
160	Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway. *Cancer Cell*, **2011**, 19, 333-46	24.3	46
159	Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 15154-9	11.5	45
158	Quantitative effect of suboptimal codon usage on translational efficiency of mRNA encoding HIV-1 gag in intact T cells. *PLoS ONE*, **2008**, 3, e2356	3.7	44
157	DC-virus interplay: a double edged sword. *Seminars in Immunology*, **2004**, 16, 147-61	10.7	44
156	Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes. *Cell Reports*, **2018**, 23, 512-521	10.6	43
155	Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. *Journal of Investigative Dermatology*, **2014**, 134, 2202-2211	4.3	42
154	Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. *Cancer Discovery*, **2019**, 9, 1192-1207	24.4	41
153	Dendritic cell immunotherapy. *Annals of the New York Academy of Sciences*, **2013**, 1284, 31-45	6.5	40
152	HIV type 1 infection of plasmacytoid and myeloid dendritic cells is restricted by high levels of SAMHD1 and cannot be counteracted by Vpx. *AIDS Research and Human Retroviruses*, **2014**, 30, 195-203	1.6	38
151	HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. *Journal of Clinical Investigation*, **2012**, 122, 4685-97	15.9	38
150	Recent advances in dendritic cell biology. *Journal of Clinical Immunology*, **2005**, 25, 87-98	5.7	37
149	Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. *Cell*, **2020**, 183, 1634-1649.e17	56.2	36
148	Computational Prediction and Validation of Tumor-Associated Neoantigens. *Frontiers in Immunology*, **2020**, 11, 27	8.4	35
147	Ion efflux and influenza infection trigger NLRP3 inflammasome signaling in human dendritic cells. *Journal of Leukocyte Biology*, **2016**, 99, 723-34	6.5	34
146	Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells. *Aids*, **2002**, 16, 171-80	3.5	34
145	HIV-1 impairs in vitro priming of naïve T cells and gives rise to contact-dependent suppressor T cells. *European Journal of Immunology*, **2010**, 40, 2248-58	6.1	33
144	Pathways utilized by dendritic cells for binding, uptake, processing and presentation of antigens derived from HIV-1. *European Journal of Immunology*, **2007**, 37, 1752-63	6.1	33

143	Resolution of immune activation defines nonpathogenic SIV infection. *Journal of Clinical Investigation*, **2009**, 119, 3512-5	15.9	33
142	Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial. *Frontiers in Immunology*, **2019**, 10, 725	8.4	32
141	Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. *Current Opinion in Immunology*, **2017**, 47, 35-43	7.8	32
140	In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection. *PLoS ONE*, **2009**, 4, e4256	3.7	32
139	Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. *American Journal of Translational Research (discontinued)*, **2009**, 1, 35-43	3	32
138	Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function. *Frontiers in Immunology*, **2013**, 4, 346	8.4	31
137	Hematopoietic progenitor kinase 1 is a negative regulator of dendritic cell activation. *Journal of Immunology*, **2009**, 182, 6187-94	5.3	31
136	Computational Pipeline for the PGV-001 Neoantigen Vaccine Trial. *Frontiers in Immunology*, **2017**, 8, 1807	8.4	30
135	Sequence-Specific Sensing of Nucleic Acids. *Trends in Immunology*, **2017**, 38, 53-65	14.4	30
134	Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation. *JCI Insight*, **2017**, 2,	9.9	30
133	Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. *Cancer Immunity*, **2010**, 10, 4		29
132	Intravenous nanoparticle vaccination generates stem-like TCF1 neoantigen-specific CD8 T cells. *Nature Immunology*, **2021**, 22, 41-52	19.1	29
131	Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses. *Cell Reports*, **2014**, 9, 1856-1870	10.6	28
130	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 450-464	12.9	28
129	Active immunization of humans with dendritic cells. *Journal of Clinical Immunology*, **2000**, 20, 167-74	5.7	27
128	Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs. *Cell*, **2021**, 184, 3962-3980.e17	56.2	26
127	Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy. *Virology*, **2009**, 383, 173-7	3.6	25
126	Plasma factors during chronic HIV-1 infection impair IL-12 secretion by myeloid dendritic cells via a virus-independent pathway. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2012**, 61, 535-44	3.1	25

125	Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. *Journal of Translational Medicine*, **2007**, 5, 2	8.5	25
124	KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity. *Journal of Clinical Investigation*, **2008**, 118, 3990-4001	15.9	25
123	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. *Cancer Cell*, **2021**, 39, 1442-1444	24.3	25
122	Current Melanoma Treatments: Where Do We Stand?. *Cancers*, **2021**, 13,	6.6	25
121	CD4 Receptor is a Key Determinant of Divergent HIV-1 Sensing by Plasmacytoid Dendritic Cells. *PLoS Pathogens*, **2016**, 12, e1005553	7.6	24
120	Differentiation of peripheral blood monocytes into dendritic cells. *Current Protocols in Immunology*, **2005**, Chapter 22, Unit 22F.4	4	23
119	Innate immune responses in primary HIV-1 infection. *Current Opinion in HIV and AIDS*, **2008**, 3, 36-44	4.2	21
118	Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.. *Nature Cancer*, **2020**, 1, 1204-1217	15.4	21
117	Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy. *Methods in Molecular Medicine*, **2005**, 109, 97-112		21
116	Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.. *Journal of Clinical Oncology*, **2016**, 34, 357-357	2.2	20
115	Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab **2017**, 5, 67		19
114	Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors. *Journal of*	5	19
113	Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. *Cancer Immunology Research*, **2020**, 8, 70-80	12.5	19
112	Requirement for innate immunity and CD90+ NK1.1? lymphocytes to treat established melanoma with chemo-immunotherapy. *Cancer Immunology Research*, **2015**, 3, 296-304	12.5	18
111	Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire. *Clinical Cancer Research*, **2009**, 15, 4467-74	12.9	18
110	Exploiting dendritic cells for active immunotherapy of cancer and chronic infections. *Molecular Biotechnology*, **2007**, 36, 131-41	3	18
109	Maturation matters: importance of maturation for antitumor immunity of dendritic cell vaccines. *Journal of Clinical Oncology*, **2004**, 22, 3834-5; author reply 3835	2.2	18
108	Dendritic cell-dead cell interactions: implications and relevance for immunotherapy. *Journal of Immunotherapy*, **2001**, 24, 294-304	5	18

107	P2X Antagonists Inhibit HIV-1 Productive Infection and Inflammatory Cytokines Interleukin-10 (IL-10) and IL-1 In a Human Tonsil Explant Model. *Journal of Virology*, **2019**, 93,	6.6	18
106	HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine. *Clinical Cancer Research*, **2009**, 15, 299-306	12.9	17
105	A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab **2018**, 6, 90		17
104	Soluble CD40 ligand contributes to dendritic cell-mediated T-cell dysfunction in HIV-1 infection. *Aids*, **2015**, 29, 1287-96	3.5	16
103	Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy. *Journal of Translational Medicine*, **2014**, 12, 342	8.5	16
102	Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment. *Frontiers in Immunology*, **2013**, 4, 436	8.4	14
101	Landscape of natural killer cell activity in head and neck squamous cell carcinoma **2020**, 8,		14
100	Stimulation of human anti-viral CD8+ cytolytic T lymphocytes by dendritic cells. *Advances in Experimental Medicine and Biology*, **1995**, 378, 375-9	3.6	14
99	Modulation of human Th17 cell responses through complement receptor 3 (CD11 b/CD18) ligation on monocyte-derived dendritic cells. *Journal of Autoimmunity*, **2018**, 92, 57-66	15.5	13
98	A reference profile-free deconvolution method to infer cancer cell-intrinsic subtypes and tumor-type-specific stromal profiles. *Genome Medicine*, **2020**, 12, 24	14.4	12
97	Dendritic cells and the promise of therapeutic vaccines for human immunodeficiency virus (HIV)-1. *Current HIV Research*, **2003**, 1, 205-16	1.3	12
96	Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy. *Journal of Visualized Experiments*, **2013**,	1.6	11
95	A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand.. *Journal of Clinical Oncology*, **2016**, 34, 9589-9589	2.2	11
94	Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 121-129	2.8	10
93	Attenuated Listeria monocytogenes vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus. *AIDS Research and Human Retroviruses*, **2015**, 31, 127-36	1.6	9
92	Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. *Clinical Cancer Research*, **2021**, 27, 4287-4300	12.9	9
91	Dendritic Cell Vaccines. *Methods in Molecular Biology*, **2016**, 1403, 763-77	1.4	9
90	CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model. *Oncogene*, **2021**, 40, 396-407	9.2	9

89	Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer. *World Journal of Urology*, **2018**, 36, 1741-1748	4	8
88	Active systemic lupus erythematosus is associated with decreased blood conventional dendritic cells. *Experimental and Molecular Pathology*, **2013**, 95, 121-123	4.4	8
87	Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients. *Cancer Journal (Sudbury, Mass.)*, **2017**, 23, 131-137	2.2	7
86	Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a Flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585] **2014**, 2, P45		7
85	Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases. *Journal of Clinical Oncology*, **2014**, 32, 3204-5	2.2	7
84	Dendritic cells in human blood and synovial exudates. *International Reviews of Immunology*, **1990**, 6, 103-16	4.6	7
83	Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.. *The Lancet Gastroenterology and Hepatology*, **2022**,	18.8	7
82	Widespread immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors		7
81	Exploiting dendritic cells for active immunotherapy of cancer and chronic infection. *Methods in Molecular Medicine*, **2005**, 109, 1-18		7
80	Spatial CRISPR genomics identifies regulators of the tumor microenvironment.. *Cell*, **2022**,	56.2	7
79	Cross-Presentation of Tumor Antigens Is Ruled by Synaptic Transfer of Vesicles among Dendritic Cell Subsets. *Cancer Cell*, **2020**, 37, 751-753	24.3	6
78	Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis **2018**, 6, 38		6
77	New interpretable machine learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy		6
76	Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy. *Oncology*, **2015**, 29, 970-2, 974-5	1.8	6
75	Activation and measurement of NLRP3 inflammasome activity using IL-1β in human monocyte-derived dendritic cells. *Journal of Visualized Experiments*, **2014**,	1.6	5
74	Dysregulation of anti-tumor immunity by the matrix metalloproteinase-2. *OncoImmunology*, **2012**, 1, 109-111	7.2	5
73	Against the self: dendritic cells versus cancer. *Apmis*, **2003**, 111, 805-17	3.4	5
72	The effect of ipilimumab on natural killer cells identifies the subset of advanced melanoma patients with clinical response.. *Journal of Clinical Oncology*, **2015**, 33, 9065-9065	2.2	5

71	DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).. *Journal of Clinical Oncology*, **2017**, 35, 300-300	2.2	5
70	Y-RNAs Lead an Endogenous Program of RIG-I Agonism Mobilized upon RNA Virus Infection and Targeted by HIV		5
69	Super(antigen) target for SARS-CoV-2. *Nature Reviews Immunology*, **2021**, 21, 72	36.5	5
68	Dendritic Cells **2017**, 126-144.e6		4
67	Biology of plasmacytoid dendritic cells and natural killer cells in HIV-1 infection. *Current Opinion in HIV and AIDS*, **2007**, 2, 189-200	4.2	4
66	Preclinical Development of a Cord Blood (CB)-Derived Hematopoietic Stem Cell (HSC) Product for Allogeneic Transplantation in Patients with Hematological Malignancies. *Blood*, **2016**, 128, 818-818	2.2	4
65	Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC).. *Journal of Clinical Oncology*, **2015**, 33, 4586-4586	2.2	4
64	A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers.. *Journal of Clinical Oncology*, **2017**, 35, TPS3114-TPS3114	2.2	4
63	Unexplored horizons of cDC1 in immunity and tolerance. *Advances in Immunology*, **2020**, 148, 49-91	5.6	4
62	MMP2 and TLRs modulate immune responses in the tumor microenvironment. *JCI Insight*, **2021**, 6,	9.9	4
61	Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.. *EClinicalMedicine*, **2022**, 45, 101323	11.3	4
60	Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy. *Vaccine*, **2015**, 33, 388-95	4.1	3
59	Turning a Tumor into a Vaccine Factory: In Situ Vaccination for Low-Grade Lymphoma. *Blood*, **2014**, 124, 5473-5473	2.2	3
58	Phase 1/2 study of in situ vaccination with tremelimumab + intravenous (IV) durvalumab + poly-ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors.. *Journal of Clinical Oncology*, **2017**, 35, TPS3106-TPS3106	2.2	3
57	A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.. *Journal of Clinical Oncology*, **2019**, 37, 9538-9538	2.2	3
56	Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. *Journal of Thoracic Oncology*, **2021**,	8.9	3
55	Computational pipeline for the PGV-001 neoantigen vaccine trial		3
54	Vaccines for immunoprevention of cancer. *Journal of Clinical Investigation*, **2021**, 131,	15.9	3

53	Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients		3
52	Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines. *Frontiers in Immunology*, **2021**, 12, 757804	8.4	3
51	Intratumoral checkpoint subversion as a strategy for minimizing adverse effects: Harvesting the power of TILs without harvesting TILs. *OncoImmunology*, **2014**, 3, e27580	7.2	2
50	Interactions of viruses with dendritic cells **2001**, 505-522		2
49	Plasmacytoid dendritic cells lead the charge against tumors. *Journal of Clinical Investigation*, **2012**, 122, 481-4	15.9	2
48	Phase II study of low-dose cyclophosphamide and ipilimumab in metastatic melanoma.. *Journal of Clinical Oncology*, **2014**, 32, e20025-e20025	2.2	2
47	In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study.. *Journal of Clinical Oncology*, **2016**, 34, 3086-3086	2.2	2
46	A phase Ib study evaluating the safety and tolerability of durvalumab in combination with eribulin in patients with HER2-negative metastatic breast cancer and recurrent ovarian cancer.. *Journal of Clinical Oncology*, **2018**, 36, TPS3116-TPS3116	2.2	2
45	A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies.. *Journal of Clinical Oncology*, **2019**, 37, e14307-e14307	2.2	2
44	P2X antagonists inhibit HIV-1 productive infection and inflammatory cytokines IL-10 and IL-1β in a human tonsil explant model		2
43	TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2020**,	2.8	2
42	Harnessing Natural Killer Cell Function for Genitourinary Cancers. *Urologic Clinics of North America*, **2020**, 47, 433-442	2.9	2
41	Perturb-map enables CRISPR genomics with spatial resolution and identifies regulators of tumor immune composition		2
40	Dendritic cells and lymphoma cells: come together right now. *Blood*, **2015**, 125, 5-7	2.2	1
39	A bloody mess: dendritic cells use hemophagocytosis to regulate viral inflammation. *Immunity*, **2013**, 39, 429-31	32.3	1
38	Influenza, but not HIV-specific CTL epitopes, elicits delayed-type hypersensitivity (DTH) reactions in HIV-infected patients. *European Journal of Immunology*, **2013**, 43, 1545-54	6.1	1
37	Dendritic cell chic. *Seminars in Immunopathology*, **2005**, 26, 215-219		1
36	Differential Expression of Type I MAGE in New and Relapsed Multiple Myeloma: Evidence for Association with Proliferation and Progression of Disease.. *Blood*, **2006**, 108, 3397-3397	2.2	1

35	Host Immune Responses Against CT Antigens in Multiple Myeloma Patients.. *Blood*, **2006**, 108, 3492-3492	2.2	1
34	Treatment of solid tumors with intratumoral poly-ICLC: A phase II clinical study.. *Journal of Clinical Oncology*, **2014**, 32, e14010-e14010	2.2	1
33	Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.. *Journal of Clinical Oncology*, **2014**, 32, TPS9119-TPS9119	2.2	1
32	Retrospective cohort analysis of adjuvant NY-ESO-1 vaccines in stage III melanoma.. *Journal of Clinical Oncology*, **2016**, 34, 3084-3084	2.2	1
31	Killed but Metabolically Active Recombinant Listeria monocytogenes as an Antigen Delivery and Activation Platform for Human Dendritic Cell-Based Cancer Immunotherapy.. *Blood*, **2004**, 104, 3447-3447	2.2	1
30	CT7 (MAGE-C1)-Specific Cellular Immune Responses in the Bone Marrow Microenvironment of Multiple Myeloma Patients.. *Blood*, **2005**, 106, 356-356	2.2	1
29	Global Cancer Transcriptome Quantifies Repeat Element Polarization Between Immunotherapy Responsive and T cell Suppressive Classes		1
28	Uncloaking Breast Tumor Neoantigens with Radiation. *Trends in Immunology*, **2021**, 42, 277-279	14.4	1
27	PD-1 inhibition in advanced myeloproliferative neoplasms. *Blood Advances*, **2021**, 5, 5086-5097	7.8	1
26	CTIM-17. PHASE I STUDY OF THE SAFETY AND IMMUNOGENICITY OF PERSONALIZED NEOANTIGEN VACCINES AND TUMOR TREATING FIELDS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. *Neuro-Oncology*, **2020**, 22, ii36-ii36	1	0
25	Association of melanoma expression of matrix metalloproteinase-23 with blunted tumor immunity and poor responses to immunotherapy.. *Journal of Clinical Oncology*, **2015**, 33, e20057-e20057	2.2	0
24	Tumor organoid-originated biomarkers predict immune response to PD-1 blockade. *Cancer Cell*, **2021**, 39, 1187-1189	24.3	0
23	A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses. *STAR Protocols*, **2021**, 2, 100758	1.4	0
22	Dendritic Cell Biology **2018**, 247-260.e6		
21	?????????????. *Nature Digest*, **2015**, 12, 30-32	0	
20	Dendritic cell function in HIV infection. *HIV Therapy*, **2009**, 3, 527-537		
19	Immune Regulation33-44		
18	Crossprocessing and Crosspresentation427-453		

17	EPCO-22. IDENTIFYING NEOANTIGENS FOR A PERSONALIZED MUTATION-DERIVED GENOMIC VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. *Neuro-Oncology*, **2020**, 22, ii73-ii74	1
16	Dendritic Cell Vaccines **2007**, 251-274	
15	621 NKG2A and HLA-E define a novel mechanism of resistance to immunotherapy with M. bovis BCG in non-muscle-invasive bladder cancer patients **2021**, 9, A651-A651	
14	314 NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer **2021**, 9, A338-A338	
13	772 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination **2021**, 9, A807-A807	
12	Martin A. "Mac" Cheever, MD: In Memoriam (1944-2021). *Cancer Immunology Research*, **2021**, 9, 1244	12.5
11	Dead-cell-associated proteins are an important source of antigens for cross-presentation by dendritic cells. *Nature Reviews Immunology*, **2004**, 4, 656-656	36.5
10	Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.. *Journal of Clinical Oncology*, **2014**, 32, 9086-9086	2.2
9	Matrix metalloproteinase-23 as a new immunotherapeutic checkpoint target in melanoma.. *Journal of Clinical Oncology*, **2014**, 32, 3030-3030	2.2
8	Association of natural killer (NK) cell exhaustion with melanoma progression.. *Journal of Clinical Oncology*, **2014**, 32, 9099-9099	2.2
7	Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 VG in patients with melanoma.. *Journal of Clinical Oncology*, **2015**, 33, e14034-e14034	2.2
6	In situ vaccine for low-grade lymphoma: Combination of intratumoral Flt3L and poly-ICLC with low-Dose radiotherapy.. *Journal of Clinical Oncology*, **2015**, 33, TPS3105-TPS3105	2.2
5	Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma. *Blood*, **2015**, 126, 1851-1851	2.2
4	Natural pattern-recognition-receptor agonists in prophylactic vaccines for in situ vaccination of lymphoma.. *Journal of Clinical Oncology*, **2016**, 34, e14516-e14516	2.2
3	Correlation of consistent blood-based gene expression with change in CTLA4 in two large independent clinical studies of patients with advanced melanoma treated with tremelimumab.. *Journal of Clinical Oncology*, **2017**, 35, 6-6	2.2
2	Trials in progress: A phase II study of in situ therapeutic vaccination against refractory solid cancers with intratumoral poly-ICLC.. *Journal of Clinical Oncology*, **2017**, 35, 166-166	2.2
1	Dendritic Cells **2013**, 117-133.e6	